Séronie-Vivien S - Search Results

1

Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

Hoppe A, Séronie-Vivien S, Thomas F, Delord JP, Malard L, Canal P, Chatelut E. Hoppe A, et al. Clin Cancer Res. 2005 Apr 15;11(8):3038-44. doi: 10.1158/1078-0432.CCR-04-2086. Clin Cancer Res. 2005. PMID: 15837759 Clinical Trial.

2

Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.

Thomas F, Séronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, Lafont T, Poublanc M, Bugat R, Chatelut E. Thomas F, et al. Clin Pharmacokinet. 2005;44(12):1305-16. doi: 10.2165/00003088-200544120-00009. Clin Pharmacokinet. 2005. PMID: 16372828 Clinical Trial.

3

Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.

Séronie-Vivien S, Toullec S, Malard L, Thomas F, Durrand V, Chatelut E. Séronie-Vivien S, et al. Med Oncol. 2006;23(1):63-73. doi: 10.1385/MO:23:1:63. Med Oncol. 2006. PMID: 16645231

4

GFR is better estimated by considering both serum cystatin C and creatinine levels.

Bouvet Y, Bouissou F, Coulais Y, Séronie-Vivien S, Tafani M, Decramer S, Chatelut E. Bouvet Y, et al. Pediatr Nephrol. 2006 Sep;21(9):1299-306. doi: 10.1007/s00467-006-0145-z. Epub 2006 Jun 22. Pediatr Nephrol. 2006. PMID: 16794818

5

Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.

Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G. Delbaldo C, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6073-8. doi: 10.1158/1078-0432.CCR-05-2596. Clin Cancer Res. 2006. PMID: 17062683

6

[Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys].

Thomas F, Séronie-Vivien S, Malard L, Chatelut E. Thomas F, et al. Therapie. 2007 Mar-Apr;62(2):121-7. doi: 10.2515/therapie:2007019. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582313 French.

7

Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study.

Léger F, Séronie-Vivien S, Makdessi J, Lochon I, Delord JP, Sarda C, Canal P, Chatelut E. Léger F, et al. Eur J Cancer. 2002 Jan;38(1):52-6. doi: 10.1016/s0959-8049(01)00358-6. Eur J Cancer. 2002. PMID: 11750839

8

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Séronie-Vivien S, LeCesne A, Vassal G; Innovative Therapies with Children with Cancer European consortium. Petain A, et al. Clin Cancer Res. 2008 Nov 1;14(21):7102-9. doi: 10.1158/1078-0432.CCR-08-0950. Clin Cancer Res. 2008. PMID: 18981009

9

Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.

Jaafar A, Séronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I. Jaafar A, et al. AIDS. 2009 Jan 14;23(2):257-9. doi: 10.1097/QAD.0b013e328314e382. AIDS. 2009. PMID: 19098496

10

Modeling the variability of creatinine measurements improves estimates of the glomerular filtration rate.

Séronie-Vivien S, Bouissou F, Dattez S, Coulais Y, Hanser AM, Hym B, Chatelut E. Séronie-Vivien S, et al. Clin Chem Lab Med. 2008;46(2):215-8. doi: 10.1515/CCLM.2008.045. Clin Chem Lab Med. 2008. PMID: 18076358

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters